RxDoctor Payments Data

Sara Cruz-Luna, MD

Internal Medicine · Clearwater, FLNPI 1023297702

Payments from drug & device makers

$1,994in general payments, 2019–2025

Across 99 payments — averaging $20.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$695
  • Lilly USA, LLC$292
  • Novo Nordisk$223
  • Pfizer$183
  • AstraZeneca$135
  • Bayer$125
  • plus $341 from 9 others

What the payments were for

  • Food & beverage$1,994100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,994 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$4,082
Medicare patients
21
Services billed
81

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide169$235,481
MounjaroTirzepatide94$138,953
JardianceEmpagliflozin88$127,728
EliquisApixaban84$90,175
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$81,046
FarxigaDapagliflozin Propanediol61$66,172
TrulicityDulaglutide27$50,857
RybelsusSemaglutide22$47,892
XareltoRivaroxaban50$46,514
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$30,596
MyrbetriqMirabegron27$21,530
Stiolto RespimatTiotropium Br/Olodaterol Hcl26$14,755
EntrestoSacubitril/Valsartan11$13,986
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$12,042
LinzessLinaclotide14$11,369

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$223$283,373191 claims
Lilly USA, LLCMounjaro, Trulicity$292$189,810121 claims
Boehringer IngelheimJardiance, Stiolto Respimat$70$142,483114 claims
GSKTrelegy Ellipta, Anoro Ellipta$695$111,64296 claims
PfizerEliquis, Paxlovid$183$92,958100 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$135$83,68586 claims
Johnson & JohnsonXarelto$14$46,51450 claims
NovartisEntresto$48$13,98611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →